Lifecycle capital ATP focuses on flexible capital across stages from pre-IP ideas to asset spinouts, presenting a sales opportunity to offer end-to-end funding solutions, strategic partnerships, and advisory services that align with portfolio company needs through seed to IPO.

Life sciences focus As a leader in life sciences venture capital with a track record of funding therapeutics, RNA-based platforms, and immuno-oncology programs, ATP is a prime potential client for discovery platforms, clinical development tools, regulatory consulting, and specialized CRO partnerships.

Strong portfolio activity Recent investments in Red Queen Therapeutics, Deep Apple Therapeutics, Deepappletx, Aulos Bioscience, Ascidian Therapeutics, and GalvanizeTx indicate ongoing expansion and a need for enabling technologies, data analytics, safety/pharmacovigilance systems, and go-to-market support.

Global ecosystem ATP collaborates with notable investors and industry players, suggesting opportunities to co-sell or co-invest, provide due diligence tooling, portfolio benchmarking, and market intelligence services to strengthen deal flow and syndication capabilities.

Tech-enabled acceleration With a tech stack spanning cloud hosting, modern web tools, data monitoring, and AI-enabled screening initiatives, ATP may need advanced data platforms, model infrastructure, security/compliance services, and EIR/venture partner support tooling to scale operations.